SLC5A2 and diabetic kidney disease: The primary outcome was annualized eGFR slope estimated from repeated measures using weighted linear mixed-effects models.<h4>Results</h4>The analytic cohort included 120 adults with non-albuminuric DKD (empagliflozin + telmisartan, n=60; telmisartan without any SGLT2 inhibitor, n=60).